에서 실시간으로 운영 중이에요! 자세히 알아보기
IDXX 아이콘

Idexx Laboratories

560.36 USD
+13.18
2.41%
장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT
프리마켓
시간외 거래
560.36
0.00
0%
1일
2.41%
5일
8.18%
1개월
9.1%
3개월
-2.73%
6개월
-1.68%
연초 이후
-16.36%
1년
-12.08%
5년
-12.21%
10년
403.6%
 

소개: Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.

직원 수: 11,000

뉴스

긍정적
중립
부정적
투자 심리 3개월
긍정적 54.3%
중립 40%
부정적 5.7%
중립
Business Wire
15일 전
IDEXX Laboratories to Release 2026 Third Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2026 Earnings Snapshot through a link on the IDEXX websi.
IDEXX Laboratories to Release 2026 Third Quarter Financial Results
중립
PRNewsWire
16일 전
Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories
Transaction marks the first realization from the now closed specialist animal health fund's inaugural vehicle CHICAGO, Sept. 30, 2026 /PRNewswire/ -- Chicago Pacific Founders ("CPF") today announced the exit of its investment in CoVetAI Inc. ("CoVet") following the company's acquisition by IDEXX Laboratories, Inc. (NASDAQ: IDXX).
Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories
중립
Zacks Investment Research
23일 전
Should You Continue to Hold IDXX Stock in Your Portfolio?
IDEXX's CAG growth, expanding software adoption and global gains face headwinds from FX and weaker U.S. vet visits.
Should You Continue to Hold IDXX Stock in Your Portfolio?
긍정적
MarketBeat
26일 전
IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets
IDEXX Laboratories NASDAQ: IDXX executives highlighted the company's diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while reaffirming confidence in its long-term growth framework despite continued pressure on veterinary office visits.
IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets
긍정적
MarketBeat
26일 전
IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference
IDEXX Laboratories NASDAQ: IDXX executives reiterated the company's long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product innovation, commercial investments and recurring-revenue economics as key drivers.
IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference
긍정적
Zacks Investment Research
29일 전
IDEXX Stock Gains Following the Acquisition of CoVet
IDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance.
IDEXX Stock Gains Following the Acquisition of CoVet
중립
Business Wire
29일 전
IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX expands Faecal Dx™ antigen testing platform in the United Kingdom with taeniid tapeworm detection for broader intestinal parasite screening.
IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
중립
Business Wire
지난달
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX announces acquisition of CoVetAI to advance veterinary workflow intelligence.
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
중립
Seeking Alpha
지난달
IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
긍정적
Seeking Alpha
지난달
Baron Partners Fund Q2 2026 Contributors And Detractors
Baron Partners Fund performed very well in the second quarter, gaining 16.61% (Institutional Shares). Top contributors include Space Exploration Technologies, Tesla, Red Rock Resorts, Hyatt Hotels and Birkenstock Holding. Top detractors include CoStar Group, Gartner, Guidewire Software, Morningstar and IDEXX Laboratories.
Baron Partners Fund Q2 2026 Contributors And Detractors
Lightweight Charts™를 사용해 가격 차트를 구현했어요.